Amycretin vs Tirzepatide
A next-gen co-agonist vs today’s approved standard
Tirzepatide (Mounjaro/Zepbound) is the approved dual agonist you can get today; amycretin is Novo Nordisk’s investigational GLP-1/amylin co-agonist — available in both injectable and oral forms in trials. Here is how the proven option compares with the most-watched pipeline challenger.
Available today vs the next wave
Tirzepatide is a GLP-1/GIP dual agonist that is FDA approved for type 2 diabetes (Mounjaro) and obesity (Zepbound), with roughly 20–22.5% weight loss in its SURMOUNT program and years of real-world data behind it. It comes premeasured in pens — no mixing, an established safety profile, and clear dosing.
Amycretin is a GLP-1/amylin co-agonist still in development. Its appeal is twofold: an oral tablet version (rare among these drugs) and the amylin mechanism, which adds satiety and may help preserve lean mass. Early subcutaneous data has been strong, but it is Phase 2 — smaller and earlier than tirzepatide’s evidence base.
The honest framing is "proven and available" versus "promising but unproven." Cross-trial weight-loss numbers are not directly comparable because the studies differ in length, dose, and participants.
Amycretin vs Tirzepatide at a glance
- ⚡Mechanism: GLP-1 + amylin co-agonist
- ⚡Routes: subcutaneous injection AND an oral tablet
- ⚡Subcutaneous Phase 1b: roughly 22% mean weight loss at 36 weeks
- ⚡Investigational — Phase 2 ongoing, not FDA approved
- ⚡Key appeal: a potential oral option + amylin-driven satiety
- ✓Mechanism: GLP-1 + GIP dual agonist
- ✓Route: once-weekly subcutaneous pen (no mixing)
- ✓SURMOUNT-1: about 22.5% mean weight loss at 72 weeks
- ✓FDA approved for obesity (Zepbound) and type 2 diabetes (Mounjaro)
- ✓Key appeal: proven Phase 3 data and availability now
Which fits your situation?
If you want treatment now, with FDA-approved Phase 3 evidence and a track record, tirzepatide is the option you can actually access — through a prescriber, insurance, or a compounding pathway. It is also the better-characterized choice for safety and dosing.
If you are specifically waiting for an oral option, or are drawn to the amylin mechanism, amycretin is the pipeline candidate to follow. But it cannot be prescribed yet, its data is earlier, and its profile may change as Phase 2 and Phase 3 results arrive.
Track now, compare later
Because there is no head-to-head trial, the most useful data for your own decision is your own response. Logging tirzepatide outcomes in Shotlee — weight trend, appetite, side effects, and labs — builds an objective baseline that makes any future switch an evidence-based decision rather than a guess.
Use this comparison as a framework and confirm the specifics with your healthcare provider, especially as amycretin’s larger trials report and the picture becomes clearer.
Amycretin vs Tirzepatide: Frequently Asked Questions
It is not proven better. Early amycretin data is strong, but it is investigational with a smaller, earlier evidence base, while tirzepatide has approved Phase 3 data (about 22.5% weight loss) and is available now. There is no head-to-head trial, so cross-study numbers are only directional.
No. They are different molecules: amycretin is a GLP-1/amylin co-agonist (developed in oral and injectable forms), while tirzepatide is a GLP-1/GIP dual agonist (injectable pens). Amycretin’s oral tablet is one reason it is closely watched, but it is not "oral tirzepatide."
Tirzepatide is available today; amycretin is not yet approved. Any future switch should be guided by a clinician. Tracking your tirzepatide outcomes in Shotlee now gives you a clean baseline for comparison if amycretin becomes available.
Subcutaneous amycretin reported roughly 22% at 36 weeks in an early-phase trial; tirzepatide produced about 22.5% at 72 weeks in SURMOUNT-1. These come from different trials of different lengths and are not directly comparable.
Yes. Shotlee logs doses, weight, side effects, and labs for your current protocol, free — so you are ready to compare if you ever change medications.
Track Your Tirzepatide Protocol in Shotlee
Free dose logging, weight trends, and side effect tracking — with a baseline ready for what comes next.